A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation
2011

Review of Techniques for Evaluating Liver Fibrosis in HCV Patients

Sample size: 200 publication Evidence: moderate

Author Information

Author(s): Ahmad Waqar, Ijaz Bushra, Gull Sana, Asad Sultan, Khaliq Saba, Jahan Shah, Sarwar Muhammad T, Kausar Humera, Sumrin Aleena, Shahid Imran, Hassan Sajida

Primary Institution: Applied and Functional Genomics Laboratory, Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan

Hypothesis

Non-invasive methods can effectively assess liver fibrosis in HCV patients and may replace liver biopsy in the future.

Conclusion

Non-invasive markers like FibroTest and Fibroscan show promise in predicting liver fibrosis stages, but none are as accurate as liver biopsy.

Supporting Evidence

  • FibroTest and Fibroscan have high predictive values for liver fibrosis.
  • Non-invasive methods are less risky than liver biopsy.
  • Genetic markers may help in differentiating fibrosis stages.

Takeaway

Doctors can use blood tests and imaging instead of a liver biopsy to check for liver damage in patients with hepatitis C.

Methodology

The review analyzed over 200 studies on invasive and non-invasive markers for diagnosing liver fibrosis in HCV patients.

Limitations

No single non-invasive marker can differentiate all stages of fibrosis, and some methods have low predictive values.

Participant Demographics

Patients with chronic hepatitis C, with a focus on various fibrosis stages.

Digital Object Identifier (DOI)

10.1186/1743-422X-8-53

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication